Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Impact of pre-existing immunity on humoral and cellular responses to CoronaVac in SARS-CoV-2 variants: A focus on common human Coronaviruses
(2025), Asian Pacific Journal of Allergy and Immunology
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Intradermal Fractional ChAdOx1 nCoV-19 Booster Vaccine Induces Memory T Cells: A Follow-Up Study
Sophonmanee R. et al, (2024), Vaccines, 12, 109 - 109
Effectiveness of plant-based hand sanitizer incorporatingQuercus infectoriagall extract
Waen-ngoen T. et al, (2023), Journal of Applied Microbiology, 134
Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
Sripongpun P. et al, (2023), Vaccines, 11, 1455 - 1455
Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report
Intapiboon P. et al, (2023), Vaccines, 11, 537 - 537
Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases.
Uea-Areewongsa P. et al, (2023), Asian Pacific journal of allergy and immunology
Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases
Intapiboon P. et al, (2022), npj Vaccines, 7
T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
Sophonmanee R. et al, (2022), Vaccines, 10, 1494 - 1494
Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population.
Pinpathomrat N. et al, (2022), NPJ vaccines, 7
Regulatory T Cells Decreased during Recovery from Mild COVID-19
Seepathomnarong P. et al, (2022), Viruses, 14, 1688 - 1688
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
Pinpathomrat N. et al, (2022), npj Vaccines, 7
Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
Intapiboon P. et al, (2021), Vaccines, 9, 1375 - 1375